Dose-ranging study of the luteinizing hormone-releasing hormone receptor antagonist cetrorelix pamoate in the treatment of patients with symptomatic benign prostatic hyperplasia

Urology

Volumn 76, Issue 4, 2010, Pages 927-933

  Debruyne, Frans ^a   Tzvetkov, Mitko ^b   Altarac, Silvio ^c   Geavlete, Petrisor A ^d  

^a RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^b MEDICAL UNIVERSITY OF SOFIA   (Bulgaria)

^c Zabok General Hospital   (Croatia)

^d Spitalul Clinic de Urgentia Sf Loan   (Romania)

Author keywords

[No Author keywords available]

Indexed keywords

CETRORELIX; CETRORELIX PAMOATE; HORMONE RECEPTOR BLOCKING AGENT; PLACEBO; TESTOSTERONE; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG DOSE REGIMEN; DRUG TOLERABILITY; HUMAN; INTERNATIONAL PROSTATE SYMPTOM SCORE; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; PRIORITY JOURNAL; PROSTATE HYPERTROPHY; RANDOMIZED CONTROLLED TRIAL; SUSTAINED DRUG RELEASE; TESTOSTERONE BLOOD LEVEL;

AGED; AGED, 80 AND OVER; DELAYED-ACTION PREPARATIONS; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; ERECTILE DYSFUNCTION; GONADOTROPIN-RELEASING HORMONE; HORMONE ANTAGONISTS; HUMANS; INJECTIONS, INTRAMUSCULAR; MALE; MIDDLE AGED; PROSTATIC HYPERPLASIA; QUALITY OF LIFE; RECEPTORS, LHRH; SEVERITY OF ILLNESS INDEX; SINGLE-BLIND METHOD; TESTOSTERONE; URINATION DISORDERS;

EID: 77957726553     PISSN: 00904295     EISSN: 15279995     Source Type: Journal    
DOI: 10.1016/j.urology.2009.09.077     Document Type: Article

References (28)

1. C.G. Roehrborn Pathology of benign prostatic hyperplasia Int J Impot Res 20 suppl 3 2008 S11 S18
2. R. Rosen, J. Altwein, and P. Boyle Lower urinary tract symptoms and male sexual dysfunction: the Multinational Survey of the Aging Male (MSAM-7) Eur Urol 44 2003 637 649
3. B.C. Taylor, T.J. Wilt, and H.A. Fink Prevalence, severity, and health correlates of lower urinary tract symptoms among older men: the MrOS study Urology 68 2006 804 809
4. F. Debruyne, P. Boyle, and F. Calais Da Silva Evaluation of the clinical benefit of permixon and tamsulosin in severe BPH patientsPERMAL study subset analysis Eur Urol 45 2004 773 779
5. K.T. McVary A review of combination therapy in patients with benign prostatic hyperplasia Clin Ther 29 2007 387 398
6. C.G. Roehrborn BPH progression: concept and key learning from MTOPS, ALTESS, combat, and ALF-ONE BJU Int 101 suppl 3 2008 17 21
7. G. Novara, A. Galfano, and R. Berto Inflammation, apoptosis, and BPH: what is the evidence? Eur Urol Suppl 5 2006 401 409
8. H. Lepor The role of gonadotropin-releasing hormone antagonists for the treatment of benign prostatic hyperplasia Rev Urol 8 2006 183 189
9. R.J. Bosch, D.J. Griffiths, and J.H. Blom Treatment of benign prostatic hyperplasia by androgen deprivation: effects on prostate size and urodynamic parameters J Urol 141 1989 68 72
10. C.A. Peters, and P.C. Walsh The effect of nafarelin acetate, a luteinizing-hormone-releasing hormone agonist, on benign prostatic hyperplasia N Engl J Med 317 1987 599 604
11. T. Reissmann, A.V. Schally, and P. Bouchard The LHRH antagonist cetrorelix: a review Hum Reprod Update 6 2000 322 331
12. D. Gonzalez-Barcena, M. Vadillo-Buenfil, and F. Gomez-Orta Responses to the antagonistic analog of LH-RH (SB-75, cetrorelix) in patients with benign prostatic hyperplasia and prostatic cancer Prostate 24 1994 84 92
13. T.M. De Reijke, K. Burk, and K. Kurth Clinical and endocrinological results of patients treated with the LHRH antagonist (cetrorelix) Eur Urol 30 1996 245
14. A.M. Comaru-Schally, W. Brannan, and A.V. Schally Efficacy and safety of luteinizing hormone-releasing hormone antagonist cetrorelix in the treatment of symptomatic benign prostatic hyperplasia J Clin Endocrinol Metab 83 1998 3826 3831
15. H. Lepor, S. Auerbach, and A. Puras-Baez A randomized double blind placebo controlled phase II study of the safety and efficacy of cetrorelix in men with BPH J Urol 157 1997 531
16. F. Debruyne, A.A. Gres, and D.L. Arustamovc Placebo-controlled dose-ranging phase II study of subcutaneously administered LHRH antagonist cetrorelix in patients with symptomatic benign prostatic hyperplasia Eur Urol 54 2008 170 177
17. Z. Culig, A. Hobisch, and M.V. Cronauer Regulation of prostatic growth and function by peptide growth factors Prostate 28 1996 392 405
18. Y. Shirahige, R.Z. Cai, and K. Szepeshazi Treatment with luteinizing hormone-releasing hormone antagonist SB-75 decreases levels of epidermal growth factor receptor and its mRNA in OV-1063 human epithelial ovarian cancer xenografts in nude mice Int J Oncol 5 1994 1031 1035
19. M.S. Steiner Review of peptide growth factors in benign prostatic hyperplasia and urological malignancy J Urol 153 1995 1085 1096
20. H.M. Behre, A. Bockers, and A. Schlingheider Sustained suppression of serum LH, FSH, and testosterone and increase of high-density lipoprotein cholesterol by daily injections of the GnRH antagonist cetrorelix over 8 days in normal men Clin Endocrinol 40 1994 241 248
21. H. Lepor The role of gonadotropin-releasing hormone antagonists for the treatment of benign prostatic hyperplasia Rev Urol 8 2006 183 189
22. J.D. McConnell, J.D. Wilson, and F.W. George Finasteride, an inhibitor of 5 alpha-reductase, suppresses prostatic dihydrotestosterone in men with benign prostatic hyperplasia J Clin Endocrinol Metab 74 1992 505 508
23. T. Tammela Benign prostatic hyperplasia Practical treatment guidelines Drugs Aging 10 1997 349 366
24. M. Marcelli, and G.R. Cunningham Hormonal signaling in prostatic hyperplasia and neoplasia J Clin Endocrinol Metab 84 1999 3463 3468
25. S. Monti, F. Di Silverio, and V. Toscano Androgen concentrations and their receptors in the periurethral region are higher than those of the subcapsular zone in benign prostatic hyperplasia (BPH) J Androl 19 1998 428 433
26. A. Tieva, P. Stattin, and P. Wikstrm Gonadotropin-releasing hormone receptor expression in the human prostate Prostate 47 2001 276 284
27. J. Engel, B. Rozsa, and A.V. Schally Luteinizing hormone-releasing hormone (LHRH) receptors in BPH as potential molecular targets for therapy with cetrorelix J Urol 179 2008 449 450
28. A. Chen, Y. Ganor, and S. Rahimipour The neuropeptides GnRH-II and GnRH-I are produced by human T cells and trigger laminin receptor gene expression, adhesion, chemotaxis and homing to specific organs Nat Med 8 2002 1421 1426